Phase to Phase - The Guide to Drug Development
Sponsored by Thermo Fisher Scientific and PPD, experts will present innovative strategies in outsourcing discovery that allows small companies to focus on their core discovery needs and frees them up from both a capital and manpower investment.
Session Topic: Diving into Phase 2 Clinical Trials
- This stage is crucial for development of new treatments to ensure safety and efficacy for a specific indication.
- Typically involve 25-100 patients with narrow enrollment criteria to assess the treatment in a relatively homogenous patient population.
- Proof of concept is main goal and will determine Phase 3 go or no-go decision.
Speakers:
- Melissa Fernandes, Global Immunology, Rheumatology & Inflammation Associate Clinical Sciences Director, PPD, part of Thermo Fisher Scientific
- Jill Parris, Senior Director, Clinical Science, PPD, part of Thermo Fisher Scientific
- Nikolay Stoyanov, Senior Director Clinical Science, Hematology/Oncology at PPD, part of Thermo Fisher Scientific
Moderator: Danko Dominis, MD, PhD, Regional Medical Officer, PPD, part of Thermo Fisher Scientific
Refund/cancellation policy: This program is offered free of charge. As such refunds are not applicable. Questions: Contact Lauren Boyle, [email protected]
